Abstract Library

#4505 NET-IMPRESS: A novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies

Introduction: Previously, we showed that analysing copy number alterations (CNAs) in cell-free DNA (cfDNA) of NET patients using shallow whole genome sequencing (sWGS) is a potential biomarker for diagnosis and follow-up (PMID: 34759042). We now present NET-IMPRESS, an easy, cost-effective methylation-based assay for detecting circulating tumour DNA (ctDNA) in NET samples.

Conference:

Presenting Author:

Authors: Mariën L, Ibrahim J, de Meulenaere N, Chhajlani S, Neefs I,

Keywords: neuroendocrine tumour, liquid biopsy, DNA methylation, copy number alterations, biomarker selection, IMPRESS technology,

#3867 Radiological follow-up (FU) in resected pulmonary typical carcinoids (pTC) – Do the benefits outweigh the risks?

Introduction: Primary resection is treatment of choice of pulmonary carcinoids (PC) and recurrences occur ~7% of TC and ~35% of atypical carcinoid (AC). Because of a risk of late recurrence, even in TC, long-term radiological FU is generally advised. As PC are frequent in relatively young pts, there is a risk of late radiation-induced cancer.

Conference:

Presenting Author: Heijboer F

Authors: Heijboer F, Mulders T, van Straten M, Moonen L, Speel E,

Keywords: pulmonary carcinoid, typical carcinoid, atypical carcinoid, primary resection, follow-up, ct scan,

#3669 Can simple measurements on routine surveillance CT in metastatic NET disease predict clinically significant carcinoid heart disease? A retrospective single site study of 73 patients

Introduction: Patients with confirmed metastatic neuroendocrine tumors (MNET) have surveillance CT scan, therefore there is acquisition of non-gated cardiac imaging.

Conference:

Presenting Author: Alessi A

Authors: Alessi A, Hughes S, Steeds R, Shah T, El-Sayed M,

Keywords: MNET, CHD, non-CHD,

#3285 Somatostatin-receptor scintigraphy in an uncommon neuroendocrine tumor

Introduction: Primary mesenteric neuroendocrine tumors (MNETs) have been rarely reported in the literature and especially their exploration with the somatostatin receptor scintigraphy (SRS) imaging which is a valuable tool for diagnostic, staging and follow-up.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Ghomari C, Benzerdjeb S, Medjahedi A,

Keywords: mesenteric neuroendocrine tumor, tektrotyd scan, metastases,

#3189 Real-world outcomes of patients with neuroendocrine liver metastases treated with trans-arterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study

Introduction: Trans-arterial radioembolization (TARE) is a treatment option for patients with liver dominant metastases from neuroendocrine tumors (mNET). The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European prospective multi-centre observational study conducted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Helmberger T

Authors: Helmberger T, Schaefer N, Pech M, Pfammatter T, Maleux G,

Keywords: liver metastases, observational study, yttrium-90, trans-arterial radioembolization, registry, therapeutic embolization, SIRT,